Lower rates of access thrombosis for patients with CKD who receive daprodustat vs. EPO
Click Here to Manage Email Alerts
Key takeaways:
- Researchers found 1,088 potential thromboembolic events.
- The first occurrence of vascular access thrombosis occurred in 164 patients receiving daprodustat vs. 201 patients who received EPO.
PHILADELPHIA — Patients with chronic kidney disease on dialysis who received daprodustat had fewer vascular access thrombosis events compared with patients who had erythropoiesis-stimulating agents, according to data presented here.
“Our results, despite the post hoc nature of it, [are] derived from a large outcome trial and are reassuring about the cardiovascular safety of daprodustat, particularly for thromboembolic events, which has been a concern for patients treated with [erythropoiesis-stimulating agents] ESAs,” Renato D. Lopes, MD, MHS, PhD, professor of medicine, division of cardiology at Duke University Medical Center, told Healio. “Patients treated with daprodustat had lower rates of vascular access thrombosis when compared with patients treated with ESAs. These findings might help physicians in the decision-making process when treating dialysis patients with anemia, especially those patients at high risk for thrombotic events.”
At ASN Kidney Week, Lopes presented post-hoc phase 3 results of the from the ASCEND-D study, which randomized 2,964 patients with CKD on dialysis and receiving ESAs to receive either daprodustat (Jesduvroq, GlaxoSmithKline) or ESA. Daprodustat is an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI).
Researchers studied the occurrence of vascular access thrombosis in the ASCEND-D study.
Vascular access thrombosis was predefined as “the absence of bruit or thrill and/or an inability to successfully initiate dialysis via the arteriovenous access after initial successful use,” according to the study abstract.
Researchers found 1,088 potential thromboembolic events, including vascular access thrombosis. The first occurrence of vascular access thrombosis occurred in 164 (11%) patients who received daprodustat and 201 (13.6%) patients who received ESA therapy.
“Based on what we have seen before in the primary results of the ASCEND-D study, we were not surprised to see the current results. It was reassuring though to see the safety profile of daprodustat on thromboembolic events, especially on vascular access thrombosis,” Lopes told Healio.
Reference:
Lopes RD, et al. TH-PO1131. Presented at: ASN Kidney Week; Nov. 1-5, 2023; Philadelphia.
Collapse
Click Here to Manage Email Alerts